Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer's disease

Frontiers in Neurology

Volumn 6, Issue NOV, 2015, Pages

  Fiandaca, Massimo S ^a   Zhong, Xiaogang ^b   Cheema, Amrita K ^b   Orquiza, Michael H ^b   Chidambaram, Swathi ^c   Tan, Ming T ^b   Gresenz, Carole Roan ^d   FitzGerald, Kevin T ^b   Nalls, Mike A ^e   Singleton, Andrew B ^e   Mapstone, Mark ^a   Federoff, Howard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RAND CORPORATION   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Economics; Ethics; Lipids; Metabolomics; Risk assessment

Indexed keywords

ACYLCARNITINE; AMINO ACID; APOLIPOPROTEIN E4; ASPARAGINE; BIOLOGICAL MARKER; DECADIENYLCARNITINE; DECENOYLCARNITINE; DODECENOYLCARNITINE; HEXADECADIENYLCARNITINE; HYDROXYOCTADECENOYLCARNITINE; HYDROXYVALERYLCARNITINE; LYSOPHOSPHATIDYLCHOLINE; METHYLMALONYLCARNITINE; N(G),N(G) DIMETHYLARGININE; NONAYLCARNITINE; PHOSPHORYLCHOLINE; PROPIONYLCARNITINE; UNCLASSIFIED DRUG; VALERYLCARNITINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC PARAMETERS; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; OBSERVATIONAL STUDY; PHENOCONVERSION; PREDICTION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VERY ELDERLY;

EID: 84949787003     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00237     Document Type: Article

References (65)

1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 7:280-92. doi:10.1016/j.jalz.2011.03.003.
2. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med (2014) 20:415-8. doi:10.1038/nm.3466.
3. Fiandaca MS, Mapstone M, Cheema AK, FederoffHJ. The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimers Dement (2014) 10:S195-211. doi:10.1016/j.jalz.2014.04.015.
4. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 39:561-77.
5. Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging (2014) 35:271-8. doi:10.1016/j.neurobiolaging.2013.08.001.
6. Guyon I. A Scaling Law for the Validation Set Training Set Ratio. Homdel, NJ: AT&T Bell Laboratories (1996).
7. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc B (1996) 58:267-88.
8. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning; Data Mining, Inference, and Prediction. New York, NY: Springer-Verlag (2008).
9. Rousseeuw PJ, Christmann A. Robustness against separation and outliers in logistic regression. Comput Stat Data Anal (2003) 43:315-32. doi:10.1016/S0167-9473(02)00304-3.
10. Youden WJ. Index for rating diagnostic tests. Cancer (1950) 3:32-5. doi:10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3.
11. Vermont J, Bosson JL, Francois P, Robert C, RueffA, Demongeot J. Strategies for graphical threshold determination. Comput Methods Programs Biomed (1991) 35:141-50. doi:10.1016/0169-2607(91)90072-2.
12. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology (2007) 29:125-32. doi:10.1159/000109998.
13. Steinberg DM, Fine J, Chappell R. Sample size for positive and negative predictive value in diagnostic research using case-control designs. Biostatistics (2009) 10:94-105. doi:10.1093/biostatistics/kxn018.
14. Alzheimer's A. 2014 Alzheimer's disease facts and figures. Alzheimers Dement (2014) 10:e47-92. doi:10.1016/j.jalz.2014.02.001.
15. Chatterjee P, Lim WLF, Gupta VB, Sorhabi HR, Taddei K, Brown B, et al. Altered plasma phospholipid composition in autosomal dominant Alzheimer's disease: a DIAN study. Alzheimers Dement (2014) 10:260. doi:10.1016/j.jalz.2014.04.412.
16. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. Anal Bioanal Chem (2014) 406:7137-48. doi:10.1007/s00216-014-8102-3.
17. Proitsi P, Kim M, Whiley L, Pritchard M, Leung R, Soininen H, et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Transl Psychiatry (2015) 5:e494. doi:10.1038/tp.2014.127.
18. Hartmann T, Van Wijk N, Wurtman RJ, Olde Rikkert MG, Sijben JW, Soininen H, et al. A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. J Alzheimers Dis (2014) 41:715-7. doi:10.3233/JAD-141137.
19. Martin V, Fabelo N, Santpere G, Puig B, Marin R, Ferrer I, et al. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis (2010) 19:489-502. doi:10.3233/JAD-2010-1242.
20. Hadaczek P, Wu G, Sharma N, Ciesielska A, Bankiewicz K, Davidow AL, et al. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model. Exp Neurol (2015) 263:177-89. doi:10.1016/j.expneurol.2014.10.010.
21. Chan RB, Oliveira TG, Cortes EP, Honig LS, DuffKE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem (2012) 287:2678-88. doi:10.1074/jbc. M111.274142.
22. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A (1992) 89:1671-5. doi:10.1073/pnas.89.5.1671.
23. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm (2000) 107:1027-63. doi:10.1007/s007020070051.
24. Grimm MO, Grosgen S, Riemenschneider M, Tanila H, Grimm HS, Hartmann T. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A (2011) 1218:7713-22. doi:10.1016/j.chroma.2011.07.073.
25. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. J Pharm Biomed Anal (2014) 98:321-6. doi:10.1016/j.jpba.2014.05.023.
26. Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids (2000) 106:1-29. doi:10.1016/S0009-3084(00)00128-6.
27. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids (2000) 35:1305-12. doi:10.1007/s11745-000-0646-3.
28. Edmond J. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J Mol Neurosci (2001) 16:181-93; discussion 215-121.
29. Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci (2014) 15:771-85. doi:10.1038/nrn3820.
30. Rapoport SI. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci (2001) 16:243-61; discussion 279-284.
31. Brecher P, Kuan HT. Lipoprotein lipase and acid lipase activity in rabbit brain microvessels. J Lipid Res (1979) 20:464-71.
32. Purdon D, Arai T, Rapoport S. No evidence for direct incorporation of esterified palmitic acid from plasma into brain lipids of awake adult rat. J Lipid Res (1997) 38:526-30.
33. Spector AA. Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci (2001) 16:159-65; discussion 215-121.
34. Sugiura T, Kudo N, Ojima T, Mabuchi-Itoh K, Yamashita A, Waku K. Coenzyme A-dependent cleavage of membrane phospholipids in several rat tissues: ATP-independent acyl-CoA synthesis and the generation of lysophospholipids. Biochim Biophys Acta (1995) 1255:167-76. doi:10.1016/0005-2760(94)00237-S.
35. Deutsch J, Rapoport SI, Purdon AD. Relation between free fatty acid and acyl-CoA concentrations in rat brain following decapitation. Neurochem Res (1997) 22:759-65. doi:10.1023/A:1022030306359.
36. Rabin O, Deutsch J, Grange E, Pettigrew KD, Chang MC, Rapoport SI, et al. Changes in cerebral acyl-CoA concentrations following ischemia-reperfusion in awake gerbils. J Neurochem (1997) 68:2111-8. doi:10.1046/j.1471-4159.1997.68052111.x.
37. Rapoport SI, Chang MCJ, Spector AA. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res (2001) 42:678-85.
38. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. J Biol Chem (1956) 222:193-214.
39. van Wijk N, Broersen LM, De Wilde MC, Hageman RJ, Groenendijk M, Sijben JW, et al. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. J Alzheimers Dis (2014) 38:459-79. doi:10.3233/JAD-130998.
40. de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. PLoS One (2014) 9:e86558. doi:10.1371/journal.pone.0086558.
41. McIntyre JA, Ramsey CJ, Gitter BD, Saykin AJ, Wagenknecht DR, Hyslop PA, et al. Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. Autoimmunity (2015) 48(5):344-51. doi:10.3109/08916934.2015.1008464.
42. Jones LL, Mcdonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res (2010) 49:61-75. doi:10.1016/j.plipres.2009.08.004.
43. Jimenez-Jimenez FJ, Molina JA, Gomez P, Vargas C, De Bustos F, Benito-Leon J, et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm (1998) 105:269-77. doi:10.1007/s007020050073.
44. Holland J, Fasanello S, Onuma T. Psychiatric symptoms associated with L-asparaginase administration. J Psychiatr Res (1974) 10:105-13. doi:10.1016/0022-3956(74)90030-2.
45. Ubuka T, Meister A. Studies on the utilization of asparagine by mouse leukemia cells. J Natl Cancer Inst (1971) 46:291-8.
46. Hubbard SC, Ivatt RJ. Synthesis and processing of asparagine-linked oligosaccharides. Annu Rev Biochem (1981) 50:555-83. doi:10.1146/annurev.bi.50.070181.003011.
47. Ruzzo EK, Capo-Chichi JM, Ben-Zeev B, Chitayat D, Mao H, Pappas AL, et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron (2013) 80:429-41. doi:10.1016/j.neuron.2013.08.013.
48. Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov (2011) 10:277-91. doi:10.1038/nrd3358.
49. Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation (2009) 119:1592-600. doi:10.1161/CIRCULATIONAHA.108.838268.
50. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J (2001) 357:593-615. doi:10.1042/0264-6021:3570593.
51. Feil R, Kleppisch T. NO/cGMP-dependent modulation of synaptic transmission. Handb Exp Pharmacol (2008) 184:529-60. doi:10.1007/978-3-540-74805-2_16.
52. Arlt S, Schulze F, Eichenlaub M, Maas R, Lehmbeck JT, Schwedhelm E, et al. Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dement Geriatr Cogn Disord (2008) 26:58-64. doi:10.1159/000144026.
53. Hamel E. The cerebral circulation: function and dysfunction in Alzheimer's disease. J Cardiovasc Pharmacol (2014) 65:317-24. doi:10.1097/FJC.0000000000000177.
54. Hall J, Viney R, Haas M. Taking a count: the evaluation of genetic testing. Aust N Z J Public Health (1998) 22:754-8. doi:10.1111/j.1467-842X.1998.tb01488.x.
55. Lliffe S, Manthorpe J. The hazards of early recognition of dementia: a risk assessment. Aging Ment Health (2004) 8:99-105. doi:10.1080/13607860410001649653.
56. Billings PR, Kohn MA, De Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet (1992) 50:476-82.
57. Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med (2008) 10:648-54. doi:10.1097/GIM.0b013e3181837217.
58. Hsu JW, Willis R. Dementia risk and financial decision making by older households: the impact of information. J Hum Cap (2013) 2013:45. doi:10.2139/ssrn.2339225.
59. Marson DC, Sawrie SM, Snyder S, McinturffB, Stalvey T, Boothe A, et al. Assessing financial capacity in patients with Alzheimer disease: a conceptual model and prototype instrument. Arch Neurol (2000) 57:877-84. doi:10.1001/archneur.57.6.877.
60. Martin R, Griffith HR, Belue K, Harrell L, Zamrini E, Anderson B, et al. Declining financial capacity in patients with mild Alzheimer disease: a one-year longitudinal study. Am J Geriatr Psychiatry (2008) 16:209-19. doi:10.1097/JGP.0b013e318157cb00.
61. Triebel KL, Martin R, Griffith HR, Marceaux J, Okonkwo OC, Harrell L, et al. Declining financial capacity in mild cognitive impairment: a 1-year longitudinal study. Neurology (2009) 73:928-34. doi:10.1212/WNL.0b013e3181b87971.
62. Karlawish J. How are we going to live with Alzheimer's disease? Health Aff(Millwood) (2014) 33:541-6. doi:10.1377/hlthaff.2014.0089.
63. Hoffman D. Alzheimer's disease legislation and policy-now and in the future. Health Aff(Millwood) (2014) 33:561-5. doi:10.1377/hlthaff.2013.1223.
64. Guttman A, Wagner JW, Allen AL, Arras JD, Atkinson BF, Farahany NA, et al. Presidential Commission for the Study of Bioethical Issues Report, GRAY MATTERS-Integrative Approaches for Neuroscience, Ethics, and Society. Washington, DC: US Dept Health and Human Services (2014). http://www.bioethics.gov/sites/default/files/Gray%20Matters%20Vol%201.pdf.
65. Goldman JS, Hahn SE, Catania JW, Larusse-Eckert S, Butson MB, Rumbaugh M, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med (2011) 13:597-605. doi:10.1097/GIM.0b013e31821d69b8.